A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. - Wikidata - awgldk - TriplyDB

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

http://www.wikidata.org/entity/Q34072975

about

Cancer microRNAs: from subtype profiling to predictors of response to therapy Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer Non-coding RNAs as theranostics in human cancers MicroRNAs in stress signaling and human disease A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer RETRACTED: Gene-gene interaction network analysis of ovarian cancer using TCGA data The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.MicroRNA binding site polymorphisms as biomarkers in cancer management and research.A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis.The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis.A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.MicroRNA signatures differentiate melanoma subtypes.KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification.Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab The impact of 3'UTR variants on differential expression of candidate cancer susceptibility genes.MicroRNA-mediated regulation of KRAS in cancer The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing Activation of KRAS promotes the mesenchymal features of basal-type breast cancer.Shielding the messenger (RNA): microRNA-based anticancer therapies.Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer.The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905 MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium.Targets of miR-200c mediate suppression of cell motility and anoikis resistance MicroRNA 135 regulates HOXA10 expression in endometriosis.RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally.Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis.MicroRNA genes and their target 3'-untranslated regions are infrequently somatically mutated in ovarian cancers MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer Single-nucleotide polymorphism in microRNA-binding site of SULF1 target gene as a protective factor against the susceptibility to breast cancer: a case-control study.Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.Childhood cancer: an emerging public health issue in China.A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis SomamiR: a database for somatic mutations impacting microRNA function in cancer.

P2860

Q24594739-18AEFF94-B20A-496C-9104-B07FEF0C7DE3 Q26827474-7B4F3DF0-ADA9-4959-AE5D-474D0AEB62DB Q26829794-EAD4AAD7-E655-4EDD-BC8B-CA02DB20BDBB Q26851250-6D19F45F-AE87-40E7-BE31-A48A3A89CFFC Q27027517-B93FAFCD-7D95-4156-AEB5-BF0AE4A2C4CF Q27851611-4C098AEC-A12F-40BC-B9E0-FBC816E1C449 Q27851690-856CC51B-8B41-495E-9C92-040CA95213AB Q28386402-74E42EFD-63F2-434A-BFDF-D30D6ED57BE1 Q28729202-72572107-5E8E-4412-B2C4-B6F38226E38A Q30374367-582E85EC-18D4-4926-BC91-8E5201D46BD6 Q33640984-3F1AD88B-141C-4DE4-92F7-68BCB24A13E2 Q33646928-6B792B80-199A-4853-95A2-856C9B014493 Q34019040-CE548540-5FCA-4156-BC6B-B7F18DDF2A97 Q34030553-41B60C2D-C085-4555-943A-C5AE09F42114 Q34134870-0852D9D2-FEBB-4A7B-BD27-3A2DE4F3ED09 Q34138308-4482B186-44C3-4C8A-9838-9BCB0AF8378F Q34182764-904121A2-B04F-48E9-B9FC-383725734BA8 Q34205192-2AD6CED9-C34C-47D9-B1CA-7089F21E4BE3 Q34205590-3A4B3798-8AA3-4B2C-9D70-54CB3E2B6C84 Q34365804-4CF41CFC-6902-4C49-82D9-629CA33E2F2D Q34483581-64549C78-89BF-4361-8FC6-337C6D5CFF5B Q34615065-50C71CD0-7EE0-4FF0-ADEB-4F0133CBB730 Q34678120-82B9858B-FE2F-426B-B831-CDD3349BFDDB Q35024008-C5C26CA4-4F89-465D-BC89-537A77BFEF26 Q35040663-585A0A14-F6AF-42B5-B074-80A2115803FE Q35070602-71B5AAAE-8BD0-4B53-9C60-2A14D29B4635 Q35079572-2DB2231C-9545-47CE-9E0C-76202D95B002 Q35147597-F8795CEA-C444-4F6A-9E3C-C553E2E46F4D Q35156802-4BE56AC2-14B9-463D-BCD1-278D7B984B76 Q35559037-E859A972-D7D9-4385-8BF0-C6889AF924B4 Q35597918-852BF8A2-F5DE-4966-BB54-88C3C59211BD Q35683647-94FC47D0-39DC-40F9-9D78-41CDC233CC2E Q35853140-DF687148-B86F-4EA6-8C83-E0E0391A943D Q35908632-806A22E3-4D14-494D-8386-27E1DA7B9458 Q36032709-C4C1404A-DF9D-400D-A805-3923FF799692 Q36044425-02756805-C4EE-4269-9834-97D57101CF61 Q36187913-8A8405C9-76D4-4DBC-B32D-B0A660A6DDA7 Q36204952-EA0FCF95-D12C-4D41-ABA5-5A276AC91DBC Q36369415-BE361BF1-5042-4669-B4A4-5821621D6FE7 Q36491386-F0DC5316-B9B0-4647-8F12-FE5EA474F1AE

P2860

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

http://www.wikidata.org/entity/Q34072975

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

@ast

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

@en

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

@nl

type

label

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

@ast

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

@en

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

@nl

prefLabel

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

@ast

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

@en

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

@nl

P1433

Q34072975-08A3A3A4-78C1-45A2-9FAD-56E50DB0D3DD

P1476

Q34072975-79B814FD-188C-4B34-9504-25DF61262FE5

P2093

Q34072975-00B64EDB-4A8C-4AB6-9F2F-1474E7C6A15B

Q34072975-06058D0F-F55B-4C03-B4EA-52256D688E28

Q34072975-0C24E09E-F42B-4D2F-8E42-0F789D154474

Q34072975-1C4CA636-818B-4160-843E-06AD2D018AE1

Q34072975-20CCA3FC-6A31-4F07-9FDC-43B1F020747A

Q34072975-2A402803-CB01-45BA-B02C-306DD836E37E

Q34072975-2B4B04C9-9864-43FD-AD81-B21800EA32E8

Q34072975-454147D2-7DBA-47FF-A4D1-3E263D46CBCF

Q34072975-506D83CC-B0F2-4D75-8864-4A085DC068D6

Q34072975-51654B28-CD34-4517-BEA1-157A18334E81

P2860

Q34072975-2BBA52B4-A754-4616-B216-28C3D82850A2

Q34072975-2D55A4EC-9EEE-41AC-A71C-B1CA779CE6A7

Q34072975-2F7DA437-679F-4487-A61F-59D214461BE1

Q34072975-3320CA08-03DE-461A-BA22-517861808EA7

Q34072975-38F7F931-535C-444F-9FCD-29C5D51478E5

Q34072975-39539488-CC8E-44E2-9B18-E4C2BF67A094

Q34072975-4622FD38-B8FF-4B3D-9F9A-93D34B887D32

Q34072975-4C1FF1B9-A6DD-4B88-AD43-88313D2E66F7

Q34072975-90E45CD4-6CDA-41C0-BAB4-9D452D08F5A3

Q34072975-97A77FC1-1F72-48E8-B93C-803FCB8223CD

P304

Q34072975-ABDDDFBA-F132-449F-9481-09031DA8CD28

P31

Q34072975-C0A9CA4D-28FF-4BFF-85FA-BB12D0807FF7

P356

Q34072975-49DFACAF-3D69-4EC0-BECF-3C80CA1DD836

P407

Q34072975-ADBB2F3E-34D6-4FAD-A5C9-36919496CCDD

P433

Q34072975-A4BA451C-DBE4-4B51-A025-7A82A8B01700

P478

Q34072975-963D63A5-616B-4588-B82D-5AFA8C2B7518

P50

Q34072975-11213505-24F7-46AA-A4E5-9601C098E76C

Q34072975-ADE6DD36-FAB2-44FF-B46F-F59CCDFA0F1C

P577

Q34072975-623125FF-DEFD-4CB7-A0C7-9A1A43BE7603

P5875

Q34072975-0C9E43DF-AEF3-42A4-B8DE-99200BC1FCD2

P698

Q34072975-A5EFB7B5-6C47-47A0-BCC1-7FD6F6C3D162

P921

Q34072975-E2FD3134-DC03-4351-9E7B-73D1914C8358

P932

Q34072975-A85EBC9E-6D8D-4816-B95A-7BDA5CF27C18

P356

0008-5472.CAN-10-0689

P1433

Cancer Research

P1476

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

@en

P2093

Alessandro Santin

http://www.w3.org/2001/XMLSchema#string

Andrew K Godwin

http://www.w3.org/2001/XMLSchema#string

Cory Pelletier

http://www.w3.org/2001/XMLSchema#string

Daniel Zelterman

http://www.w3.org/2001/XMLSchema#string

Elena Ratner

http://www.w3.org/2001/XMLSchema#string

Ellen Matloff

http://www.w3.org/2001/XMLSchema#string

Harvey Risch

http://www.w3.org/2001/XMLSchema#string

Herbert Yu

http://www.w3.org/2001/XMLSchema#string

Lena J Chin

http://www.w3.org/2001/XMLSchema#string

Lingeng Lu

http://www.w3.org/2001/XMLSchema#string

P2860

A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers

A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk

RAS is regulated by the let-7 microRNA family

Cancer statistics, 2008

Oncomirs - microRNAs with a role in cancer

Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival

Common genetic variation and human traits

MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN

MicroRNA expression and identification of putative miRNA targets in ovarian cancer.

A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.

P304

6509-6515

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-10-0689

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Joanne B. Weidhaas

P577

2010-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45278433

http://www.w3.org/2001/XMLSchema#string

P698

20647319

http://www.w3.org/2001/XMLSchema#string

P921

P932

2923587

http://www.w3.org/2001/XMLSchema#string